|
|
|
|
|
|
Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
ClinicalTrials.gov Identifier: | NCT00000477 |
To conduct a pilot study to determine whether lowering elevated serum cholesterol levels with 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG CoA) reductase inhibitors reduced mortality due to the sequelae of atherosclerotic cardiovascular disease in older men and women.
Condition | Intervention | Phase |
Atherosclerosis Cardiovascular Diseases Coronary Disease Heart Diseases Hypercholesterolemia Myocardial Ischemia |
Drug: lovastatin |
Phase II |
Genetics Home Reference related topics: | hypercholesterolemia |
MedlinePlus related topics: | Cholesterol Heart Diseases |
Drug Information available for: | Cholest-5-en-3-ol (3beta)- Lovastatin |
Study Type: | Interventional |
Study Design: | Prevention, Randomized |
Ages Eligible for Study: | 65 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Men and women, ages 65 and older, with elevated low-density lipoprotein cholesterol levels between 159 and 221 mg/dl at entry.
Investigator: | William Applegate | University of Tennessee |
Investigator: | John Crouse | Bowman Gray School of Medicine |
Investigator: | Donald Hunninghake | University of Minnesota |
Investigator: | Robert Knopp | University of Washington |
Investigator: | John LaRosa | George Washington University |
Study ID Numbers: | 66 |
First Received: | October 27, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00000477 |
Health Authority: | United States: Federal Government |
|
|
|
|